{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:46:27Z","timestamp":1792125987058,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin (TTR) gene-silencing therapies have transformed the management of variant transthyretin amyloidosis with polyneuropathy (ATTRv-PN). However, real-world evidence on effectiveness, safety and durability is limited. We conducted a multicenter retrospective study across ten Spanish referral hospitals including 98 genetically confirmed ATTRv-PN amyloidosis patients treated with patisiran (n\u2009=\u200981) or inotersen (n\u2009=\u200917). Patients were classified as total, partial, or non-responders according to clinical evolution and Neuropathy Impairment Score (NIS). Baseline clinical, neurophysiological (CMAP, SNAP, ESC), and biochemical parameters were analyzed. Longitudinal NIS changes, treatment persistence, and safety were assessed. Total responders had higher baseline CMAP amplitudes (p\u2009=\u20090.045), while baseline neurophysiological measures showed modest discriminatory capacity overall, with electrochemical skin conductance providing the strongest signal. Baseline renal function differed across groups (eGFR, p\u2009=\u20090.022), but the direction of this association was not consistent with improved response. Compared with inotersen, patisiran showed a higher total response rate (59.3% vs. 23.5%), slower NIS progression (median\u2009+\u20090.31 vs. +4.00 points\/year; p\u2009=\u20090.011), and greater treatment persistence (log-rank p\u2009=\u20090.0005). No discontinuations due to adverse events occurred with patisiran, versus 41.2% with inotersen. ESC showed the highest predictive value (AUC 0.681 overall; 0.783 in the patisiran subgroup), while baseline NIS was less informative. In routine practice, patisiran was associated with more favourable effectiveness and tolerability compared to inotersen. Baseline neurological preservation, particularly motor and small-fiber measures, may help identify patients more likely to benefit from treatment. However, these findings should be interpreted with caution due to the limited sample-size and the observational nature of the study.<\/jats:p>","DOI":"10.1038\/s41598-026-62140-y","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:55:27Z","timestamp":1784134527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and clinical predictors of response to first-generation TTR silencers in variant ATTR amyloidosis with polyneuropathy"],"prefix":"10.1038","volume":"16","author":[{"given":"M. A.","family":"Ribot-Sans\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gonz\u00e1lez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bayon-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Borrachero-Garro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garc\u00eda-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mu\u00f1oz-Beamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Casasnovas-Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alejaldre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ant\u00f3n-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez-Torr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kapetanovic-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Galan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heine-Su\u00f1er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ventayol-Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mart\u00ednez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hern\u00e1ndez-Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Losada-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4109-4635","authenticated-orcid":false,"given":"Eugenia","family":"Cisneros-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"4","key":"62140_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","volume":"29","author":"JN Buxbaum","year":"2022","unstructured":"Buxbaum, J. N. et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 29 (4), 213\u2013219. https:\/\/doi.org\/10.1080\/13506129.2022.2147636 (2022).","journal-title":"Amyloid"},{"key":"62140_CR2","doi-asserted-by":"publisher","unstructured":"Poli, L. et al. Hereditary transthyretin amyloidosis: A comprehensive review with a focus on peripheral neuropathy. Front. Neurol. 14. https:\/\/doi.org\/10.3389\/fneur.2023.1242815 (2023).","DOI":"10.3389\/fneur.2023.1242815"},{"issue":"1","key":"62140_CR3","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson, M. M. et al. Cardiac amyloidosis: Evolving diagnosis and management: A Scientific statement from the American Heart Association. Circulation 142 (1), E7\u2013E22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792 (2020).","journal-title":"Circulation"},{"key":"62140_CR4","doi-asserted-by":"publisher","unstructured":"Delgado, D. et al. Epidemiology of transthyretin (ATTR) amyloidosis: A systematic literature review. Orphanet J. Rare Diseases. https:\/\/doi.org\/10.1186\/s13023-025-03547-0 (2025).","DOI":"10.1186\/s13023-025-03547-0"},{"key":"62140_CR5","unstructured":"TTR[GENE] - ClinVar - NCBI. (n.d.). Retrieved February 22, from (2026). https:\/\/www.ncbi.nlm.nih.gov\/clinvar"},{"issue":"9","key":"62140_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg, F. L. & Maurer, M. S. Cardiac amyloidosis due to transthyretin protein. JAMA 331 (9), 778\u2013791. https:\/\/doi.org\/10.1001\/jama.2024.0442 (2024).","journal-title":"JAMA"},{"issue":"6","key":"62140_CR7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams, D. et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J. Neurol. 268 (6), 2109\u20132122. (2021). https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J. Neurol."},{"key":"62140_CR8","doi-asserted-by":"publisher","unstructured":"Gertz, M. et al. Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam. Pract. 21 (1). https:\/\/doi.org\/10.1186\/s12875-020-01252-4 (2020).","DOI":"10.1186\/s12875-020-01252-4"},{"key":"62140_CR9","doi-asserted-by":"publisher","unstructured":"Lin, X. et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol. 21 (1). https:\/\/doi.org\/10.1186\/s12883-021-02094-y (2021).","DOI":"10.1186\/s12883-021-02094-y"},{"key":"62140_CR10","doi-asserted-by":"publisher","unstructured":"Dyck, P. J. B. et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS\u2009+\u20097. J. Neurol. Sci.  https:\/\/doi.org\/10.1016\/j.jns.2019.116424 (2019).","DOI":"10.1016\/j.jns.2019.116424"},{"issue":"5","key":"62140_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/mus.25563","volume":"56","author":"PJ Dyck","year":"2017","unstructured":"Dyck, P. J. et al. Assessing mNIS+7Ionis and international neurologists\u2019 proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve. 56 (5), 901\u2013911. https:\/\/doi.org\/10.1002\/mus.25563 (2017).","journal-title":"Muscle Nerve"},{"issue":"2","key":"62140_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik, E. J. et al. Norfolk QOL-DN: Validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J. Peripheral Nerv. Syst. 19 (2), 104\u2013114. https:\/\/doi.org\/10.1111\/jns5.12059 (2014).","journal-title":"J. Peripheral Nerv. Syst."},{"key":"62140_CR13","doi-asserted-by":"publisher","unstructured":"Gragera-Mart\u00ednez, \u00c1. et al. Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis. Front. Neurol. 16 https:\/\/doi.org\/10.3389\/fneur.2025.1660344 (2025).","DOI":"10.3389\/fneur.2025.1660344"},{"issue":"1","key":"62140_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","volume":"31","author":"S Ticau","year":"2024","unstructured":"Ticau, S. et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid 31 (1), 1\u201311. https:\/\/doi.org\/10.1080\/13506129.2023.2232520 (2024).","journal-title":"Amyloid"},{"issue":"3","key":"62140_CR15","doi-asserted-by":"publisher","first-page":"E412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96 (3), E412\u2013E422. https:\/\/doi.org\/10.1212\/WNL.0000000000011090 (2021).","journal-title":"Neurology"},{"issue":"1","key":"62140_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379 (1), 11\u201321. https:\/\/doi.org\/10.1056\/nejmoa1716153 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"62140_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cardiogenetics12020017","volume":"12","author":"F Dongiglio","year":"2022","unstructured":"Dongiglio, F. et al. Modified body mass index as a novel nutritional and prognostic marker in patients with cardiac amyloidosis. Cardiogenetics 12 (2), 185\u2013197. https:\/\/doi.org\/10.3390\/cardiogenetics12020017 (2022).","journal-title":"Cardiogenetics"},{"issue":"6","key":"62140_CR18","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s10072-024-07311-3","volume":"45","author":"E Moreno-Moraleda","year":"2024","unstructured":"Moreno-Moraleda, E. et al. Validating the usefulness of Sudoscan in ATTRv: A single centre experience. Neurol. Sci. 45 (6), 2859\u20132867. https:\/\/doi.org\/10.1007\/s10072-024-07311-3 (2024).","journal-title":"Neurol. Sci."},{"issue":"1","key":"62140_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10286-017-0467-x","volume":"29","author":"P Novak","year":"2019","unstructured":"Novak, P. Electrochemical skin conductance: A systematic review. Clin. Autonom Res. 29 (1), 17\u201329. https:\/\/doi.org\/10.1007\/s10286-017-0467-x (2019).","journal-title":"Clin. Autonom Res."},{"issue":"1","key":"62140_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/nejmoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379 (1), 22\u201331. https:\/\/doi.org\/10.1056\/nejmoa1716793 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"62140_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams, D. et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30 (1), 18\u201326. https:\/\/doi.org\/10.1080\/13506129.2022.2091985 (2023).","journal-title":"Amyloid"},{"issue":"13","key":"62140_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam, S. J. Vutrisiran: First approval. Drugs 82 (13), 1419\u20131425. https:\/\/doi.org\/10.1007\/s40265-022-01765-5 (2022).","journal-title":"Drugs"},{"issue":"15","key":"62140_CR23","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330 (15), 1448\u20131458. https:\/\/doi.org\/10.1001\/jama.2023.18688 (2023).","journal-title":"JAMA"},{"key":"62140_CR24","doi-asserted-by":"publisher","unstructured":"Monteiro, C. et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 4 (12). https:\/\/doi.org\/10.1172\/jci.insight.126526 (2019).","DOI":"10.1172\/jci.insight.126526"},{"issue":"3","key":"62140_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","volume":"82","author":"D Adams","year":"2025","unstructured":"Adams, D. et al. Five-Year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: A randomized clinical trial with open-label extension. JAMA Neurol. 82 (3), 228\u2013236. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4631 (2025).","journal-title":"JAMA Neurol."},{"issue":"9","key":"62140_CR26","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.medcli.2024.01.008","volume":"162","author":"MAR Sanso","year":"2024","unstructured":"Sanso, M. A. R. et al. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy. Med. Clin. 162 (9), e27\u2013e32. https:\/\/doi.org\/10.1016\/j.medcli.2024.01.008 (2024).","journal-title":"Med. Clin."},{"key":"62140_CR27","doi-asserted-by":"publisher","unstructured":"Concei\u00e7\u00e3o, I. Early diagnosis in ATTRv amyloidosis, How early is enough? How early is possible?. Med. Clin. 162 (12), e70\u2013e73. https:\/\/doi.org\/10.1016\/j.medcli.2024.02.013 (2024).","DOI":"10.1016\/j.medcli.2024.02.013"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62140-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:43Z","timestamp":1792123783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62140"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62140-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9019314\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.R.-S., J.G.-M., C.B.-G., C.B.-G., F.M.-B., C.C.-P., A.A., A.A.-V., T.S.-M., R.F.-T., S.K.G., L.G., R.E., F.M.-V., P H.-S., I.L.-L., and E.C.-B. have received support for conference attendance and\/or honoraria for advisory or speaking activities from Alnylam Pharmaceuticals and Sobi. M.V.-G., S.G.-G. and D.H-S. declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Approval was obtained from Balearic Islands Research Ethics Committee [CEIm-IB] with the reference code (IB 5669\/24 EOm), and all data were anonymized prior to analysis.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation and revision of this manuscript, the authors used Julius AI for data analysis assistance, support in the interpretation and presentation of results. The software is identified as Julius AI, web-based platform, accessed between April 2025 and April 2026. All AI-assisted outputs were independently reviewed, verified, and revised by the authors, who made all final decisions regarding the analyses, interpretation, and conclusions reported in the manuscript. The authors assume full responsibility for the accuracy, integrity, and final content of the submitted work.","order":3,"name":"Ethics","label":"AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32536"}}